Al Waili 1999.

Methods	Study design: parallel RCT Study duration: NS Duration of follow‐up: 24 h
Participants	Country: UAE Setting: multicentre Diagnosis based in general urine examination, IV urogram, US and the voiding of a calculus Number: treatment group 1 (30); treatment group 2 (34) Mean age (range): 28 years (18 to 42) Sex (M/F): 52/12 Exclusion criteria: hepatic or cardiovascular diseases; allergy to NSIADs; received antispasmodics, pethidine, or any other prostaglandin synthesis inhibitors with 2 hours of study
Interventions	Treatment group 1 Diclofenac: 75 mg (IM) Treatment group 2 Piroxicam: 40 mg (IM)
Outcomes	VAS‐10: 30, 60 min (measured at 15 min intervals for up to 8 h and hourly for 24 h after treatment) Need for rescue after 1st hour of treatment
Notes	Source of funding: NS
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Not reported
Allocation concealment (selection bias)	Unclear risk	Not reported
Blinding (performance bias and detection bias) Medication used	Low risk	Double blind, participants and investigators
Incomplete outcome data (attrition bias) All outcomes	Low risk	No missing outcome data
Selective reporting (reporting bias)	Low risk	All pre‐specified primary and secondary outcomes are reported
Other bias	Low risk	The study appears to be free of other sources of bias